Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 12:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: human papillomavirus vaccine, recombinant Clear all
Completed No phase listed Observational

Gardasil Knowledge

NCT03083249
View directory record Official record
Conditions
HPV
Interventions
Gardasil
Other
Lead sponsor
Sarah Hostetter, MD
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 10, 2026, 12:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Preparedness Study - HPV Vaccine

NCT01489527
View directory record Official record
Conditions
Sexual Transmission of Infection
Interventions
Gardasil Vaccine, Placebo
Biological · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years to 24 Years · Female only
Enrollment
406 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2015 · Synced Oct 10, 2026, 12:53 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study

NCT01133509
View directory record Official record
Conditions
Genital Human Papilloma Virus Infection
Interventions
Gardasil
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 10, 2026, 12:53 AM EDT
Recruiting Phase 2 Interventional

pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

NCT05799144
View directory record Official record
Conditions
Metastatic Oropharyngeal Carcinoma, Recurrent Oropharyngeal Carcinoma
Interventions
DNA Vaccine, Human Papillomavirus Tumor Antigen Vaccine, Pembrolizumab, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Magnetic Resonance Imaging, Biopsy
Biological · Procedure
Lead sponsor
Michael K. Gibson
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Birmingham, Alabama • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 10, 2026, 12:53 AM EDT
Active, not recruiting Phase 2 Interventional

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

NCT03519464
View directory record Official record
Conditions
Idiopathic CD4 T Cell Lymphocytopenia
Interventions
Gardasil 9
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 10, 2026, 12:53 AM EDT
Completed Phase 2 Interventional Results available

Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

NCT00513526
View directory record Official record
Conditions
Infection, Precancerous Condition
Interventions
Gardasil
Biological
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 10, 2026, 12:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Randomized Trial of Alternative HPV Vaccination Schedules in Males in a University Setting

NCT01184079
View directory record Official record
Conditions
Quadrivalent HPV Vaccine, Human Papillomavirus Vaccine
Interventions
quadrivalent human papillomavirus vaccine
Biological
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 26 Years · Male only
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 10, 2026, 12:53 AM EDT
Withdrawn Early Phase 1 Interventional

Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis

NCT00829608
View directory record Official record
Conditions
Recurrent Respiratory Papillomatosis
Interventions
Human Papillomavirus Vaccine
Biological
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 10, 2026, 12:53 AM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

NCT01492582
View directory record Official record
Conditions
Cancer Survivor, Prevention of Human Papillomavirus Infection
Interventions
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58), laboratory biomarker analysis, survey administration, medical chart review
Biological · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
9 Years to 26 Years
Enrollment
1,499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
5
States / cities
Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 10, 2026, 12:53 AM EDT
Terminated Phase 4 Interventional Results available

HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions

NCT03051516
View directory record Official record
Conditions
High Grade Anal Canal Intraepithelial Neoplasia, High Grade Vulvar Squamous Intraepithelial Lesion
Interventions
Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
Other · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
27 Years to 69 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Birmingham, Alabama • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 10, 2026, 12:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Intralesional HPV Vaccine for Condylomata

NCT05087849
View directory record Official record
Conditions
Human Papilloma Virus, Warts, Warts, Genital, Condyloma, Condylomata Acuminata
Interventions
nonavalent human papillomavirus vaccine
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 10, 2026, 12:53 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

NCT05985681
View directory record Official record
Conditions
Human Papillomavirus-Related Carcinoma
Interventions
Biospecimen Collection, HPV16 RG1 VLP Vaccine, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
Procedure · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 60 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 10, 2026, 12:53 AM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

NCT01209325
View directory record Official record
Conditions
Anal Cancer, Nonneoplastic Condition, Penile Cancer, Precancerous Condition
Interventions
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, laboratory biomarker analysis
Biological · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
13 Years to 26 Years · Male only
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
18
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 10, 2026, 12:53 AM EDT
Recruiting Phase 2Phase 3 Interventional

Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

NCT05625633
View directory record Official record
Conditions
Warts
Interventions
Human Papillomavirus 9-valent Vaccine, Recombinant, Normal Saline
Biological · Other
Lead sponsor
Western Institute for Veterans Research
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 10, 2026, 12:53 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

NCT04199689
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
9vHPV Vaccine, Placebo (Saline for Injection)
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
6,033 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
32
States / cities
Northridge, California • Rialto, California • Simi Valley, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 10, 2026, 12:53 AM EDT
Recruiting Phase 2 Interventional

HPV Vaccine, Imiquimod, and Metformin Combination Trial

NCT06686043
View directory record Official record
Conditions
Cervical Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma
Interventions
HPV vaccine, Imiquimod, and metformin combination therapy
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 10, 2026, 12:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

NCT01424644
View directory record Official record
Conditions
Meningococcal Meningitis
Interventions
Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
Biological
Lead sponsor
Novartis
Industry
Eligibility
11 Years to 18 Years
Enrollment
801 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
17
States / cities
Birmingham, Alabama • Fremont, California • Madera, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 10, 2026, 12:53 AM EDT
Completed Not applicable Interventional Results available

The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata

NCT00941889
View directory record Official record
Conditions
HIV Positive, Anal Condylomata, Anal Warts, HIV Infections
Interventions
Saline, Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 10, 2026, 12:53 AM EDT
Active, not recruiting Phase 4 Interventional

Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

NCT03023631
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Recombinant Human Papillomavirus Nonavalent Vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 10, 2026, 12:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting

NCT00572832
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Quadrivalent human papillomavirus vaccine on-time administration, Quadrivalent human papillomavirus vaccine delayed administration
Biological
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 23 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 10, 2026, 12:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Adolescent Vaccination in Pharmacies

NCT01960088
View directory record Official record
Conditions
Evaluating Attitudes Toward HPV Vaccinations in Pharmacies, Evaluating the Provision of HPV Vaccines in a Pharmacy
Interventions
HPV vaccine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
11 Years to 18 Years
Enrollment
1,509 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 10, 2026, 12:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

NCT00423046
View directory record Official record
Conditions
Infections, Papillomavirus, Papillomavirus Vaccines
Interventions
GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM), Gardasil ® (Merck & Co. Inc), Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
40
States / cities
Chandler, Arizona • San Diego, California • San Francisco, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 10, 2026, 12:53 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department

NCT06229353
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Gardasil 9
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 45 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 10, 2026, 12:53 AM EDT
Completed Not applicable Interventional Results available

Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women

NCT00786409
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Gardasil
Biological
Lead sponsor
University of Chicago
Other
Eligibility
9 Years to 26 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 10, 2026, 12:53 AM EDT